Must have taken some patience to hold that during the past few months where it was consolidating ! Bugger on missing out on that but hey theres always oppurtunites though :)
Printable View
Brilliant, Sparky!! Love both the music and PEB. Enjoy your comments.
Garfy.
In at average 2.55, out at 5.50, I can't complain. Still holding some but not as many as I would like :-(
Sparky's right about this one, the success of PEB is just around the corner I think too. When they start selling to the US/Europe is when we will see some more amazing gains. To top that off, I think they will be sustainable gains backed up by actual profits and dividend payments (I am picking first dividend in the first half of next year!).
I don't work like that. The money I am investing in shares is money that I can afford to lose (relatively speaking) and invest long term for the divies. Therefore my sell price/profit price is based on (in the order I think about them):
1. When the companies fundamentals change or its potential is exhausted.
2. When there are other better oppourtunities on the market.
3. I need the money (in the case of Diligent I could have used money from other investments but the break cost was too high, I planned a little poorly).
4. When my wife needs the money :-)
For PEB, the price I might start selling is above $6, if the company continues to go from strength to strength and the above factors don't come into play. At that stage they will have a good dividend stream though so even then I will only sell if I want to do something silly like buy a house.
Oh yeah - I probably aren't a big investor (holding 40k PEB with it being my second largest holding), so for me the reward/risks aren't massive. For others holding more it probably will be!
I'm with Blobbles for what its worth (and have said as much in previous posts). At my stage of life, I need to take aggressive positions to help fund the "after work" period. Have a large s/h at an average price of about 24c and if it goes, it goes. But I am confident it will grow rather well. Why not ride it ...they are a great company with a great outlook IMHO.
From http://www.finnewsnetwork.com.au/Com...d,-RM-Research
Quote:
According to most recent update from PEB’s management the company is on track to get CLIA certification by the end of March with commercial launch to follow shortly after.
Quote:
The US is the largest market opportunity for the Cxbladder and PEB is building a laboratory for the provision of the Cxbladder test to urologists and physicians across the US. The laboratory will be regulated under the Clinical Laboratories Improvement Amendment Act (CLIA) which will enable PEB to offer Cxbladder as a Laboratory Developed Test meaning it would not require FDA approval.Pacific Edge estimates that the annual potential US market for bladder cancer tests is approximately 1.8M tests. PEB uses the following assumptions to estimate the market:
- In the United States 1,000,000 patients per year present to their GP with haematuria;
- 68,800 patients are diagnosed each year with bladder cancer1;
- NCCN Clinical Practice Guidelines in Oncology specify that patients receive 12 monitoring cystoscopies in the five year monitoring period – 4 in the year of diagnosis and 2 in each following year.
All in all, PEB estimates 1,825,000 assays to be required per year. PEB’s new facility in Hershey, Pennsylvania would have a capacity of producing 260K tests per annum. These represents 14% of the overall market.
PEB expects smooth reimbursement process in US. A third party market survey of Medical and Benefits Review Committees for Health Insurers in the US that covered a wide spectrum of private plans showed a very high level of acceptance and concordance with the payers systems.
According to PEB, total supported price for Cxbladder using composite CPT coding for CMS patients is expected to be approximately US$786 per test. Reimbursement by insurers in the US generally occurs at 70% to 80% of the composite CPT code, meaning it will be in the range of US$550 - US$630 per test.